Pharma Execs Urge Post-Brexit Regulatory Deal, As EMA Focuses On Redistribution Of MHRA Work

Spurred by an apparent shift towards a more pro-business stance among government ministers, a number of top pharmaceutical executives and heads of UK industry bodies have publicly called for some form of regulatory alignment deal between the UK and the EU after Brexit.